DEA Temporarily Bans 7-OH: What Families Need to Know About This Potent Opioid-Like Compound

On July 1, 2026, the U.S. Drug Enforcement Administration (DEA) filed notices of intent to temporarily place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act. This federal action follows growing reports of overdose deaths, addiction, and adverse health effects linked to concentrated synthetic 7-OH products sold in gas stations, convenience stores, and online.

What Happened

The DEA's action targets four specific substances:

7-hydroxymitragynine (7-OH) — above a specified concentration threshold
Mitragynine pseudoindoxyl
MGM-15
MGM-16

Once the temporary scheduling orders take effect, the manufacture, distribution, sale, and possession of these substances will become subject to criminal, civil, and administrative provisions of the Controlled Substances Act — the same legal framework that applies to heroin, LSD, and fentanyl analogues.

Important distinction: This action does not apply to traditional botanical kratom products containing naturally occurring 7-OH below the specified threshold. The DEA is specifically targeting synthesized products and those containing elevated concentrations of 7-OH, which laboratory analysis shows often contain significantly higher amounts than found in natural kratom leaf.

What Is 7-OH?

7-hydroxymitragynine is a psychoactive compound with opioid-like effects. While it occurs in trace amounts in the Mitragyna speciosa plant (commonly known as kratom), commercial products often contain concentrated or semi-synthetic versions created through chemical modification.

These products appear in various forms:

Powders and capsules
Tablets and gummies
Dissolvable strips
"Candy-like" formulations

They are widely marketed online and sold in gas stations, convenience stores, and smoke shops — often without age restrictions or quality controls.

Clinical Risks and Consequences

Overdose Potential

7-OH produces classic opioid toxidrome, including:

Respiratory depression (slowed or stopped breathing)
Pinpoint pupils
Unresponsiveness
Cyanosis (bluish skin from oxygen deprivation)

Research indicates that 7-OH can induce respiratory depression comparable to morphine. The Los Angeles County Medical Examiner has confirmed fatal overdoses in otherwise healthy adults attributed to 7-OH use.

Addiction and Dependence

Regular use of 7-OH can lead to physical dependence and addiction. Withdrawal symptoms mirror those of traditional opioids:

Anxiety and restlessness
Muscle aches and body pain
Insomnia
Sweating and tremors
Nausea and vomiting
Intense cravings

Users have described withdrawals similar to those from heroin and fentanyl. The compound's longer half-life compared to naloxone means that even when overdose is reversed, patients may require repeat dosing or continuous naloxone infusion and extended medical observation.

Unpredictable Effects

DEA laboratory findings indicate that commercial 7-OH products vary widely in potency and purity. Some contain significantly higher concentrations than labeled, while others may be contaminated with additional substances. This unpredictability creates serious risks even for experienced users.

What This Ban Means for Families

Immediate Changes

Once the temporary scheduling takes effect:

Legal consequences: Possession, sale, or distribution becomes a federal offense
Supply disruption: Retailers will likely remove products from shelves
Online sales: E-commerce platforms will face increased pressure to remove listings

For Current Users

If someone in your family is using 7-OH products:

Do not stop suddenly if physically dependent — withdrawal can be severe. Consult a healthcare provider for a supervised taper.
Naloxone works — While 7-OH has a longer half-life than naloxone, naloxone can still reverse respiratory depression. Multiple doses may be needed.
Seek medical help for any signs of overdose: slow breathing, unresponsiveness, or blue lips/fingertips. Call 911 immediately.

Harm Reduction Strategies

Never use alone — Have someone present who can call for help
Carry naloxone — Keep multiple doses available and know how to use them
Avoid mixing — Do not combine with alcohol, benzodiazepines, or other depressants
Start low — If using, begin with the smallest possible amount
Know the signs — Learn to recognize overdose symptoms

What Families Should Watch For

Be aware if your loved one:

Purchases products from gas stations or smoke shops labeled as "kratom," "kava," or "natural supplements"
Uses dissolvable strips or gummies for energy or pain relief
Experiences withdrawal symptoms when stopping use
Has developed tolerance requiring increasing amounts

Where to Get Help

For immediate assistance:

SAMHSA National Helpline: 1-800-662-HELP (4357) — Free, confidential, 24/7 treatment referral
Poison Control: 1-800-222-1222 — 24/7 expert guidance for suspected overdose
Emergency: Call 911 for any suspected overdose

For treatment and support:

Find treatment providers at SAMHSA's treatment locator
Narcotics Anonymous: na.org for peer support meetings
SMART Recovery: smartrecovery.org for science-based mutual aid

The Bottom Line

The DEA's temporary scheduling of 7-OH represents a significant federal response to an emerging public health threat. While this action targets dangerous synthetic products rather than traditional botanical kratom, families should understand that concentrated 7-OH poses real risks of overdose, addiction, and severe withdrawal.

If you or someone you love is using these products, now is the time to seek help. The temporary ban will make these substances harder to obtain — but for those already dependent, medical support can make stopping safer and more successful.

This alert was medically reviewed by Dr. Rachel Bennett, MD, a board-certified addiction medicine physician. The information is current as of July 2, 2026, and reflects the DEA's Notice of Intent filed July 1, 2026. For the latest updates, consult the DEA website or speak with a healthcare provider.